<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085250</url>
  </required_header>
  <id_info>
    <org_study_id>2019-FXY-119</org_study_id>
    <nct_id>NCT04085250</nct_id>
  </id_info>
  <brief_title>Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy</brief_title>
  <official_title>A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase II, randomised Study is to explore the efficacy and safety of nivolumab as
      consolidation therapy in patients with locally advanced, unresectable non-small cell lung
      cancer (stage III) who have not progressed following neoadjuvant chemotherapy plus nivolumab
      and definitive concurrent chemoradiation therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">November 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the efficacy of Nivolumab consolidation compared with observation in terms of progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the efficacy of Nivolumab consolidation compared with observation in terms of Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the efficacy of Nivolumab consolidation compared with observation in terms of Objective Response Rate; To assess the efficacy of neoadjuvant chemotherapy plus nivolumab in terms of objective response rate after neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the safety of Nivolumab consolidation compared with observation in terms of adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms and Health-related Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the symptoms and health-related quality of life in patients treated with Nivolumab consolidation compared with observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the efficacy of neoadjuvant chemotherapy plus nivolumab in terms of progression-free survival for all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the efficacy of neoadjuvant chemotherapy plus nivolumab in terms of overall survival for all patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Stage III Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nivolumab Consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in experimental group will receive Nivolumab consolidation (480 mg) via iv infusion Q4W±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neoadjuvant therapy</intervention_name>
    <description>The neoadjuvant therapy before radiotherapy comprised of Docetaxel 75 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.</description>
    <arm_group_label>Nivolumab Consolidation</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chemotherapy concurrent with radiotherapy</intervention_name>
    <description>Docetaxel 25 mg/m2 for 1 hour +Cisplatin 25 mg/m2, once a week (QW)</description>
    <arm_group_label>Nivolumab Consolidation</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Simultaneousintegrated boost intensity-modulated radiation therapy(SIB-IMRT) technique was used to deliver a definitive radiation dose</description>
    <arm_group_label>Nivolumab Consolidation</arm_group_label>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab consolidation (480 mg) via iv infusion once every 4 weeks (Q4W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q4W schedule for a maximum duration of 12 months.</description>
    <arm_group_label>Nivolumab Consolidation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For inclusion in neoadjuvant therapy, patients should fulfil the following criteria:

               -  Provision of signed, written and dated informed consent prior to any study
                  specific procedures；

               -  Male or female aged 18~75 years old；

               -  Patients must have histologically- or cytologically-documented NSCLC who present
                  with locally advanced, unresectable (Stage III) disease;

               -  Without prior chemotherapy, radiotherapy, surgery, targeted therapy or
                  immunotherapy;

               -  Tumour sample requirements: Mandatory provision of an unstained, archived tumour
                  tissue sample in a quantity sufficient to allow for analysis;

               -  A recent tumour biopsy (taken following completion of the most recent therapy) is
                  an optional requirement, provided that a biopsy procedure is technically feasible
                  and the procedure is not associated with unacceptable clinical risk;

               -  Life expectancy ≥12 weeks;

               -  World Health Organization (WHO) Performance Status of 0 or 1;

               -  Evidence of post-menopausal status, or negative urinary or serum pregnancy test
                  for female pre-menopausal patients within 14 days before the use of study drug
                  (HCG has a minimum sensitivity of 25 IU/L or equivalent);

               -  Women must be non-breastfeeding

               -  Women of reproductive age (WOCBP) must agree to comply with the contraceptive
                  method during the study nivolumab treatment and for a period of 5 months
                  following the last administration of the study treatment (i.e., 30 days
                  [ovulation cycle] plus approximately 5 half-lives of the study drug).

               -  Men who have sex with WOCBP must agree to comply with the contraceptive method
                  during the study nivolumab treatment and for 7 months after the last
                  administration of the study treatment (i.e. 90 days [sperm renewal cycle] plus
                  approximately 5 half-life of the study drug).

               -  Spermless men do not have to comply with contraceptive requirements. WOCBP who
                  continues to be asexual with the opposite sex does not have to comply with
                  contraceptive requirements, but must still undergo the pregnancy tests described
                  in this section.

               -  Adequate organ and marrow function as defined below:

          -  Forced expiratory volume in 1 second (FEV1) ≥800ml

          -  Absolute neutrophil count &gt;1.5 x 109/L (1500 per mm3)

          -  Platelets &gt;100 x 109/L (100,000 per mm3)

          -  Haemoglobin≥9.0 g/dL (5.59 mmol/L)

          -  Serum creatinine clearance(CL) &gt;50 mL/min by the Cockcroft-Gault formula (Cockcroft
             and

             -Gault 1976)

          -  Serum bilirubin ≤1.5 x upper limit of normal (ULN). ··Aspartate Transaminase(AST) and
             Alanine Transaminase(ALT) ≤2.5 x ULN

        Exclusion Criteria:

          -  Exclusion criteria for enrolment for neoadjuvant therapy

        Patients should not enter the study if any of the following exclusion criteria are
        fulfilled:

          -  Concurrent enrolment in another clinical study, unless it is an
             observational(non-interventional) clinical study;

          -  Mixed small cell and non-small cell lung cancer histology;

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of Nivolumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid. Systemic steroid administration required
             to manage toxicities arising from radiation therapy delivered as part of the
             chemoradiation therapy for locally advanced NSCLC is allowed.

          -  Prior exposure to any anti-programmed cell death protein(PD)-1 or anti-PD-L1 antibody;

          -  Recent major surgery within 4 weeks prior to entry into the study (excluding the
             placement of vascular access) that would prevent administration of nivolumab;

          -  Active or prior documented autoimmune disease within the past 2 years;

          -  Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative
             colitis);

          -  History of primary immunodeficiency;

          -  History of organ transplant that requires therapeutic immunosuppression;

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from3
             electrocardiograms (ECGs) using Bazett's Correction;

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any patient known to have hepatitis B, hepatitis C or
             human immunodeficiency virus (HIV), or psychiatric illness/social situations that
             would limit compliance with study requirements or compromise the ability of the
             patient to give written informed consent;

          -  Known history of tuberculosis;

          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within30
             days of receiving nivolumab;

          -  History of another primary malignancy within 5 years prior to starting nivolumab,
             except for adequately treated basal or squamous cell carcinoma of the skin or cancer
             of the cervix in situ and the disease under study;

          -  Female patients who are pregnant, breast-feeding or male or female patients of
             reproductive potential who are not employing an effective method of birth control;

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the nivolumab or interpretation of patient safety or study results.

        Exclusion criteria for concurrent chemoradiation following neoadjuvant therapy

        Patients should not enter the concurrent chemoradiation phase if any of the following
        exclusion criteria are fulfilled:

          -  Patients who develop distant metastasis;

          -  Patients who develop locoregional disease progression and the irradiation dose of
             normal tissue will exceed the limit as defined in Section 7.

          -  World Health Organization (WHO) Performance Status of 2-4;

          -  Inadequate organ and marrow function as defined below:

               -  Forced expiratory volume in 1 second (FEV1) &lt;800ml

               -  Absolute neutrophil count &lt;1.5 x 109/L (1500 per mm3)

               -  Platelets &lt;100 x 109/L (100,000 per mm3)

               -  Haemoglobin&lt;9.0 g/dL (5.59 mmol/L)

               -  Serum creatinine CL &lt;50 mL/min by the Cockcroft-Gault formula (Cockcroft and

          -  Gault 1976)

               -  Serum bilirubin &gt;1.5 x upper limit of normal (ULN).

               -  Aspartate Transaminase(AST) and Alanine Transaminase(ALT) &gt;2.5 x ULN

        Further exclusion criteria for randomization into Nivolumab consolidation or observation
        group

        Patients should not enter the randomization if any of the following exclusion criteria are
        fulfilled:

          -  Patients who have progressed whilst definitive platinum based, concurrent
             chemoradiation therapy;

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of Nivolumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid. Systemic steroid administration required
             to manage toxicities arising from radiation therapy delivered as part of the
             chemoradiation therapy for locally advanced NSCLC is allowed.

          -  Any unresolved toxicity CTCAE &gt;Grade 2 from the prior chemoradiation therapy will be
             excluded from randomization;

          -  Patients with Grade ≥2 pneumonitis from prior chemoradiation therapy will be excluded
             from randomization; Any prior Grade ≥3 immune-related adverse event (irAE) while
             receiving any previous immunotherapy agent, or any unresolved irAE&gt;Grade 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hui Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, MD</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Liu, MD</last_name>
    <phone>+86-020-87343031</phone>
    <email>liuhui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weineng Feng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun yat-sen university cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The first affliated hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>WenHua Liang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013 Mar;45(1):1-14. doi: 10.4143/crt.2013.45.1.1. Epub 2013 Mar 31.</citation>
    <PMID>23613665</PMID>
  </reference>
  <reference>
    <citation>Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007 Aug;2(8):706-14. Erratum in: J Thorac Oncol. 2007 Oct;2(10):985.</citation>
    <PMID>17762336</PMID>
  </reference>
  <reference>
    <citation>Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF 3rd, Green MR. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990 Oct 4;323(14):940-5.</citation>
    <PMID>2169587</PMID>
  </reference>
  <reference>
    <citation>Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991 Mar 20;83(6):417-23.</citation>
    <PMID>1847977</PMID>
  </reference>
  <reference>
    <citation>Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992 Feb 20;326(8):524-30.</citation>
    <PMID>1310160</PMID>
  </reference>
  <reference>
    <citation>Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996 Apr;14(4):1065-70.</citation>
    <PMID>8648358</PMID>
  </reference>
  <reference>
    <citation>Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995 Feb;13(2):452-8.</citation>
    <PMID>7844608</PMID>
  </reference>
  <reference>
    <citation>Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60. doi: 10.1093/jnci/djr325. Epub 2011 Sep 8. Erratum in: J Natl Cancer Inst. 2012 Jan 4;104(1):79.</citation>
    <PMID>21903745</PMID>
  </reference>
  <reference>
    <citation>Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999 Sep;17(9):2692-9.</citation>
    <PMID>10561343</PMID>
  </reference>
  <reference>
    <citation>Aupérin A, Le Péchoux C, Pignon JP, Koning C, Jeremic B, Clamon G, Einhorn L, Ball D, Trovo MG, Groen HJ, Bonner JA, Le Chevalier T, Arriagada R; Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol. 2006 Mar;17(3):473-83.</citation>
    <PMID>16500915</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol. 2018 Mar 5;9:185. doi: 10.3389/fphar.2018.00185. eCollection 2018. Review.</citation>
    <PMID>29556198</PMID>
  </reference>
  <reference>
    <citation>Sacco PC, Maione P, Guida C, Gridelli C. The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer. Curr Clin Pharmacol. 2017;12(1):4-10. doi: 10.2174/1574884711666161201123439. Review.</citation>
    <PMID>27908252</PMID>
  </reference>
  <reference>
    <citation>Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.</citation>
    <PMID>28885881</PMID>
  </reference>
  <reference>
    <citation>Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.</citation>
    <PMID>29658848</PMID>
  </reference>
  <reference>
    <citation>Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):775-81. doi: 10.1016/j.ijrobp.2009.02.032. Epub 2009 Jun 8.</citation>
    <PMID>19515503</PMID>
  </reference>
  <reference>
    <citation>Franceschini D, Paiar F, Meattini I, Agresti B, Pasquetti EM, Greto D, Bonomo P, Marrazzo L, Casati M, Livi L, Biti G. Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer. Laryngoscope. 2013 Dec;123(12):E97-103. doi: 10.1002/lary.24257. Epub 2013 Jun 26.</citation>
    <PMID>23775348</PMID>
  </reference>
  <reference>
    <citation>Wu B, McNutt T, Zahurak M, Simari P, Pang D, Taylor R, Sanguineti G. Fully automated simultaneous integrated boosted-intensity modulated radiation therapy treatment planning is feasible for head-and-neck cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):e647-53. doi: 10.1016/j.ijrobp.2012.06.047. Epub 2012 Aug 3.</citation>
    <PMID>22867890</PMID>
  </reference>
  <reference>
    <citation>Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e201-7. doi: 10.1016/j.ijrobp.2012.12.008.</citation>
    <PMID>23517808</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>May 24, 2020</last_update_submitted>
  <last_update_submitted_qc>May 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Stage III Non-Small Cell Lung Cancer</keyword>
  <keyword>Neoadjuvant Chemotherapy plus nivolumab</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Nivolumab consolidation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

